{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wei H"],"funding":["NIDDK NIH HHS","NIAID NIH HHS","NHLBI NIH HHS"],"pagination":["32"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5696535"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["2"],"pubmed_abstract":["Delivery of a gene of interest to target cells is highly desirable for translational medicine, such as gene therapy, regenerative medicine, vaccine development, and studies of gene function. Parainfluenza virus 5 (PIV5), a paramyxovirus with a negative-sense RNA genome, normally infects cells without causing obvious cytopathic effect, and it can infect many cell types. To exploit these features of PIV5, we established a system generating self-amplifying, virus-like particles (AVLP). Using enhanced green fluorescent protein (EGFP) as a reporter, AVLP encoding EGFP (AVLP-EGFP) successfully delivered and expressed the EGFP gene in primary human cells, including stem cells, airway epithelial cells, monocytes, and T cells. To demonstrate the application of this system for vaccine development, we generated AVLPs to express the HA and M1 antigens from the influenza A virus strain H5N1 (AVLP-H5 and AVLP-M1H5). Immunization of mice with AVLP-H5 and AVLP-M1H5 generated robust antibody and cellular immune responses. Vaccination with a single dose of AVLP-H5 and M1H5 completely protected mice against lethal H5N1 challenge, suggesting that the AVLP-based system is a promising platform for delivery of desirable genes."],"journal":["NPJ vaccines"],"pubmed_title":["Developing a platform system for gene delivery: amplifying virus-like particles (AVLP) as an influenza vaccine."],"pmcid":["PMC5696535"],"funding_grant_id":["P30 DK054759","P01 HL091842","P01 HL051670","P01 AI060699"],"pubmed_authors":["Sakamoto K","Tompkins SM","Elson A","Jones C","Stice S","Phan S","Li Z","Chen Z","Abraham M","McCray PB","Kristhnamurthy S","Andrews S","Wei H","He B"],"additional_accession":[]},"is_claimable":false,"name":"Developing a platform system for gene delivery: amplifying virus-like particles (AVLP) as an influenza vaccine.","description":"Delivery of a gene of interest to target cells is highly desirable for translational medicine, such as gene therapy, regenerative medicine, vaccine development, and studies of gene function. Parainfluenza virus 5 (PIV5), a paramyxovirus with a negative-sense RNA genome, normally infects cells without causing obvious cytopathic effect, and it can infect many cell types. To exploit these features of PIV5, we established a system generating self-amplifying, virus-like particles (AVLP). Using enhanced green fluorescent protein (EGFP) as a reporter, AVLP encoding EGFP (AVLP-EGFP) successfully delivered and expressed the EGFP gene in primary human cells, including stem cells, airway epithelial cells, monocytes, and T cells. To demonstrate the application of this system for vaccine development, we generated AVLPs to express the HA and M1 antigens from the influenza A virus strain H5N1 (AVLP-H5 and AVLP-M1H5). Immunization of mice with AVLP-H5 and AVLP-M1H5 generated robust antibody and cellular immune responses. Vaccination with a single dose of AVLP-H5 and M1H5 completely protected mice against lethal H5N1 challenge, suggesting that the AVLP-based system is a promising platform for delivery of desirable genes.","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017","modification":"2024-11-09T23:23:55.109Z","creation":"2019-03-27T03:02:34Z"},"accession":"S-EPMC5696535","cross_references":{"pubmed":["29263887"],"doi":["10.1038/s41541-017-0031-7"]}}